Mydecine Innovations Group MYCO MYCOF (FSE:0NFA) reported its financial results on Tuesday and provided a business update for the third quarter ended September 30.
Q3 2021 Financial Highlights
- Net loss attributable to common stockholders was $4.5 million, or a basic and diluted loss per share attributable to common stockholders of $0.02, as compared to a net loss attributable to common stockholders of $17.4 million for the third quarter 2020, or a basic and diluted loss per share attributable to common stockholders of $0.11.
- As of September 30, the Denver-based company had cash and cash equivalents of $1.6 million.
Business Highlights During and Subsequent To Q3 2021
Clinical Trials
- Prepared to supply its lead drug candidate, MYCO-001, for a JHU multi-site NIDA grant-funded smoking cessation study led by Dr. Matthew Johnson.
- Announced upcoming launch of seamless Phase 2/3 smoking cessation clinical trial studying the science and efficacy of MYCO-001.
- Inked a five-year research deal with JHU School of Medicine to advance clinical trials and explore multiple molecules and medicines for a variety of indications.
“This marks the first time in over 50 years that the U.S government has funded a study of a psychedelic compound for therapeutics,” Joshua Bartch, CEO of Mydecine said. “As we prepare for the launch of these trials, we expect to meet with the FDA for Pre-Investigational New Drug Application (Pre-IND) meetings in early 2022, another step closer to bringing to market more effective treatments for today’s unmet needs in mental health and addiction.”
IP Portfolio
- Filed final patent application for MYCO-003 with the United States Patent and Trademark Office and the World Intellectual Property Organization, which is being developed to offer enhanced treatment of anxiety and PTSD.
- Filed new patent for MDMA-like compounds.
- Filed a technology patent that allows for creating formulations that utilize nanoemulsion technology to enhance, stabilize and make repeatable properties of ingredients from traditional medicine.
Technology
- Launched Mindleap 2.0, an updated version of its virtual health platform, which adds focus on the conscious and trustworthy adoption of psychedelics into the broader categories of mental health.
- Continued development of AI-driven drug discovery program.
Corporate
Completed its spin-out transaction of ALT House Cannabis Inc., which now holds the Company’s U.S. cannabis assets.
MYCOF Price Action
Mydecine Innovations’ shares traded 3.80% lower at $0.1684 per share at the time of writing on Tuesday afternoon.
Photo: Courtesy of Mydecine Innovations Group
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.